comparemela.com

Latest Breaking News On - Pharmaceuticals biotechnology companies - Page 5 : comparemela.com

Lateral Flow Assays Market is projected to reach a valuation of US$ 6.9 billion at a CAGR of 4.7% by

The Lateral Flow Assays Market is anticipated to be valued at US$ 4.3 billion in 2023, growing to US$ 6.9 billion by 2033. During the forecast period, lateral flow assay sales are expected to expand at a CAGR of 4.7%.The market profited from the COVID-19 pandemic. The use of lateral flow test kits, which are smaller.

New-york
United-states
Delaware
United-kingdom
China
Scanwell-health-mobile-app
Pharmaceuticals-biotechnology-companies
Market-insights-inc
Neumodx-molecular-inc
Roche-ltd
Thermo-fisher-scientific-inc

Fluid Management Devices Market to Reach $13.29 Billion, Globally, by 2031 at 11.3% CAGR: Allied Market Research

/PRNewswire/ Allied Market Research published a report, titled, "Fluid Management Devices Market by Product Type (Fluid management systems, Fluid management.

United-states
Portland
Oregon
Hong-kong
United-kingdom
Pune
Maharashtra
India
America
Karl-storz
David-correa
Pawan-kumar

Peptide Synthesis Market | Bachem Holding AG, Thermo Fisher Scientific Inc, Merck KGaA, Kaneka Corpo

The Peptide Synthesis Market is anticipated to reach US$ 520.0 million in 2023 and US$ 1.1 billion by 2033. During the forecast period, the market is expected to grow at a CAGR of 8%. As per the Peptide Synthesis Market survey by Future Market Insights (FMI), the peptide synthesis market is forecasted to register a.

New-york
United-states
Delaware
America
Cdmos-cros
Asia-pacific
Novo-nordisk
Academics-research-institutes
World-health-organization
Pharmaceuticals-biotechnology-companies
Genscript-biotech-corporation
Market-insights-inc

Lateral Flow Assay Market is projected to reach a valuation of US$ 6.9 billion by 2033

The lateral flow assay market is predicted to be worth US$ 4.3 billion in 2023, rising to US$ 6.9 billion by 2033. Throughout the forecast period, lateral flow assay sales are expected to grow at a CAGR of 4.7%.The lateral flow assay (LFA) is a well-known commercial tool in the field of on-site diagnosis because it.

New-york
United-states
Delaware
Mexico
United-kingdom
Brazil
Asia-pacific
Eurofins-technologie-rapidscan
Roche-ltd
Human-services
Pharmaceuticals-biotechnology-companies
Quidel-corporation

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.